ABIVAX Société Anonyme (NASDAQ:ABVX) Receives $38.67 Consensus Target Price from Brokerages

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have been assigned an average rating of “Buy” from the seven brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $38.67.

Several equities research analysts recently weighed in on the company. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. JMP Securities started coverage on ABIVAX Société Anonyme in a report on Wednesday, December 4th. They set an “outperform” rating and a $33.00 price target on the stock.

ABIVAX Société Anonyme Stock Performance

ABVX opened at $7.45 on Friday. The company’s 50 day moving average is $8.75 and its 200-day moving average is $10.67. ABIVAX Société Anonyme has a 1-year low of $6.53 and a 1-year high of $17.02.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ABVX. GAMMA Investing LLC acquired a new position in shares of ABIVAX Société Anonyme during the fourth quarter valued at about $29,000. BNP Paribas Financial Markets lifted its holdings in shares of ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares in the last quarter. Walleye Capital LLC boosted its position in shares of ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after buying an additional 80,807 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after buying an additional 119,300 shares in the last quarter. Finally, abrdn plc raised its position in ABIVAX Société Anonyme by 167.7% in the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after buying an additional 198,225 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.